Basiliximab can be administered safely and effectively in a single dose on day 1 postrenal transplantation in patients receiving triple therapy with azathioprine.
Matl
I
I
Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Bachleda
P
P
Michalsky
R
R
Navratil
P
P
Lao
M
M
Treska
V
V
Prestele
H
H
Matthisson
M
M
Korn
A
A
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use*; D000077552:Basiliximab; D001938:Brazil; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology / Q000473:pathology / Q000517:prevention & control; D006650:Histocompatibility Testing; D006801:Humans; D007165:Immunosuppression Therapy / Q000592:standards; D007239:Infections / Q000453:epidemiology; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology; D011993:Recombinant Fusion Proteins; D012449:Safety; D013997:Time Factors
D000911:Antibodies, Monoclonal; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab; D001379:Azathioprine